News Releases

Taiho Pharmaceutical Co., Ltd. announced on March 7, 2017 that it has established its subsidiary Taiho Pharma Canada, Inc. in Oakville, Ontario.

The establishment of Taiho Pharma Canada was motivated by the recent successful NDA approval and commercial launch of Lonsurf^® (IND code: TAS-102, nonproprietary names: trifluridine and tipiracil hydrochloride), Taiho’s first cancer product in the US. Lonsurf is currently marketed in Japan, the US and Europe. Taiho Pharma Canada will prepare for an NDA submission and for potential commercialization of the product in Canada.

Ross Glover, VP and General Manager of Taiho Pharma Canada, has a proven track record as a successful commercial executive with experience in building and providing strong strategic leadership to specialty products business units, including oncology. Prior to joining Taiho Pharma Canada, Glover led commercial organizations in large and medium sized bio-pharma companies in Canada. His extensive experience will be an asset to meeting the challenges of establishing Taiho Pharma Canada and managing the NDS process and potential commercialization for Lonsurf.

The establishment of Taiho Pharma Canada represents another step towards the globalization of the Taiho Group and providing cancer patients throughout the world with new and innovative chemotherapies for treatment of a wide range of tumor types.